DDrare: Database of Drug Development for Rare Diseases

16. クロウ・深瀬症候群
［臨床試験数：12，薬物数：18（DrugBank：8），標的遺伝子数：5，標的パスウェイ数：79］

Searched query = "Crow-Fukase syndrome", "POEMS syndrome", "Polyneuropathy, organomegaly, endocrinopathy, m-protein, and skin changes syndrome", "Takatsuki disease", "PEP syndrome", "Polyneuropathy, endocrinopathy, plasma cell dyscrasia syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Cyclophosphamide; Daratumumab; Daratumumab Injection; Dexamethasone; FPF 300 (thalidomide); G-CSF; Ixazomib; Ixazomib Citrate; Lenalidomide; Lenalidomide and dexamethasone; Lenalidomide+Dexamethasone; Lenalidomide, Dexamethasone; Lenograstim; Other: Laboratory Biomarker Analysis; Other: Questionnaire Administration; REVLIMID*21CPS 25MG; Revlimid; Thalidomide

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01816620 (ClinicalTrials.gov)	March 2014	14/3/2013	Study to Evaluate Lenalidomide Plus Dexamethasone in Patients With Newly Diagnosed POEMS Syndrome	An Open-label Phase II Study to Determine the Efficacy and Safety of Lenalidomide Plus Dexamethasone (LDex) in Patients With Newly Diagnosed POEMS Syndrome	POEMS Syndrome	Drug: Lenalidomide , Dexamethasone	Peking Union Medical College Hospital	Celgene Corporation	Completed	18 Years	N/A	All	41	Phase 2	China

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT01816620
(ClinicalTrials.gov)

March 2014

14/3/2013

Study to Evaluate Lenalidomide Plus Dexamethasone in Patients With Newly Diagnosed POEMS Syndrome

An Open-label Phase II Study to Determine the Efficacy and Safety of Lenalidomide Plus Dexamethasone (LDex) in Patients With Newly Diagnosed POEMS Syndrome

POEMS Syndrome

Drug: Lenalidomide , Dexamethasone

Peking Union Medical College Hospital

Celgene Corporation

Completed

18 Years

N/A

All

Phase 2

China